Healthcare is big business, and investors looking for stable, long-term growth stocks should look no further than Merck & Co. (NYSE: MRK) and GlaxoSmithKline (NYSE: GSK). Both are significant players in the pharmaceutical industry, and both companies offer investors some great investment options with low volatility that pay dividends.
Let's take a closer look to see which of these is the better option today.
Merck gives investors both value and growth
Despite showing some impressive growth in its most recent quarter, Merck's share price has risen just 10% in 2019. It has been carried in part by the strong success of Keytruda, a cancer-fighting drug that could be integral to the company's long-term success. With Keytruda improving the survival rate of patients suffering from lung cancer, there's a lot of potential to help Merck generate even more success in the years to come, especially as it receives approval to use Keytruda for more treatment options. Most recently, the U.S. Food and Drug Administration gave it the OK for treating certain types of melanoma.
From a growth perspective, Merck has a lot of appeal. But what makes it an even better buy is that unlike smaller pharma stocks that may have a long way to go to become good investments, Merck is already there. With revenues north of $42 billion last year and profits of more than $6 billion, the company is already producing some very strong results. And with free cash flow of more than $8 billion, the company is in a great position to take on growth initiatives, even including potential acquisitions.
IMAGE SOURCE: GETTY IMAGES.
Its dividend of 2.6% is another added bonus for investors. The only negative is that the stock is a bit expensive today, trading at around 24 times earnings and eight times its book value.
GlaxoSmithKline has some great growth opportunities as well
GlaxoSmithKline (GSK) has had near mirror results to Merck this year, and there hasn't been a lot separating the two stocks. Like Merck, the company also has an exciting product in Shingrix, which has been very effective in preventing shingles. That could help drive a lot of growth, especially amid an aging U.S. demographic that could see demand for the product rise in the future. Shingrix was recently approved for use in China as well. In addition, the company also has Zejula, a drug showing good progress in treating ovarian cancers, that could also be key to long-term growth.
While GSK is smaller than Merck, the company has also produced some strong results over the years. Sales of $30.8 billion in 2018 have grown by 29% in three years, from $23.9 billion in 2015. It has also generated a strong operating income of more than $6 billion in each of the past four years and looks on pace to continue to do that again this year.
A look at valuation shows us that GSK is the more expensive of the two stocks, trading at more than 40 times earnings and a whopping 17 times book value. GSK, does, however, pay a higher yield, with its dividend up around 4.4%.
Image Source: YCharts
Why Merck wins it for me
Although it pays a higher dividend, GSK is simply too expensive to buy today, and Merck's stronger, more consistent financials help make it a safer all-around investment. However, both stocks could achieve a lot of growth over the years, and investors who buy GSK could be very happy with their results as well.
10 stocks we like better than Merck & Co.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Merck & Co. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 1, 2019
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.